Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for managing adverse events in patients with inflammation

A patient-inflammation technology, applied in the field of controlling adverse events in patients with inflammation, can address issues such as increased morbidity and mortality

Pending Publication Date: 2021-09-07
HEMANEXT INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of crystalloids leads to increased morbidity and mortality by causing trauma-induced coagulopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for managing adverse events in patients with inflammation
  • Methods for managing adverse events in patients with inflammation
  • Methods for managing adverse events in patients with inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0158]Embodiment 1. A method for treating low mean arterial pressure in a subject in need thereof, the method comprising providing stored oxygen-reduced blood to the subject having low mean arterial pressure caused by hemorrhagic trauma , the oxygen-reduced blood has an initial oxygen saturation of 20% or less and is maintained at an oxygen saturation of 20% or less for a storage period.

Embodiment 2

[0159] Embodiment 2. The method of embodiment 1, wherein after said providing, said mean arterial pressure in said subject in need thereof is increased relative to patients receiving routinely stored blood.

Embodiment 3

[0160] Embodiment 3. The method of embodiment 1 or 2, wherein the hemorrhagic trauma is selected from the group consisting of surgery, penetrating trauma, blunt force trauma, fall injury, and auto accident injury.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for prevention and reversal of inflammation are disclosed.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 768,667, filed November 16, 2018. [0003] government rights [0004] This invention was made with US Government support under R44HL132172 awarded by the National Heart, Lung, and Blood Institute. The government has certain rights in this invention. technical field [0005] The present disclosure relates to the treatment of inflammation, sickle cell disease, trauma and hemorrhagic shock. Background technique [0006] Sickle cell disease (SCD), a group of inherited red blood cell disorders, affects millions of people worldwide. SCD is estimated to affect approximately 100,000 Americans. [0007] Sickle cell disease is divided into 6 categories, sickle cell anemia (HbSS), hemoglobin C sickle cell anemia (HbSC), hemoglobin S-β-thalassemia ((HbSβ0 and Hbβ+ thalassemia), hemoglobin SD disease (HbSD ), hemoglobin SE disease (HbSE), and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/14A61P7/06A61P29/00A61P31/00A61P9/10A61P7/00A61P9/02
CPCA61K35/14A61P7/06
Inventor 安德鲁·邓纳姆吉田达郎塞缪尔·O·索韦米莫-科克尔
Owner HEMANEXT INC